TheraCryf
Private Company
Funding information not available
Overview
TheraCryf is a clinical-stage biotech developing innovative small molecule therapies for high-unmet-need brain disorders, with a strategy centered on proof-of-concept development followed by partnership with larger pharma. Its pipeline includes two advanced preclinical assets: a 'best-in-class' orexin-1 antagonist (Ox-1) for addictive behaviors and anxiety, and an atypical dopamine transporter inhibitor (DAT) for fatigue and narcolepsy. A third asset, SFX-01 (a stabilized sulforaphane), is being explored in glioblastoma via an external collaboration. The company is pre-revenue and aims to advance its lead program to clinic readiness by 2026.
Technology Platform
Focused small molecule drug development targeting specific neuroreceptors (orexin-1) and transporters (dopamine transporter) with candidates designed for improved specificity and side-effect profiles.
Opportunities
Risk Factors
Competitive Landscape
The neuropsychiatry space is highly competitive with numerous large pharma and biotech companies developing therapies for addiction, anxiety, and eating disorders. TheraCryf's differentiation lies in its specific orexin-1 antagonist profile and its atypical DAT inhibitor approach, aiming for better tolerability. In glioblastoma, the competitive landscape is intense, but SFX-01's novel mechanism (stabilized sulforaphane) offers a differentiated approach.